LXRX Articles, Lexicon Pharmaceuticals Inc. - From 10/11/23

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of ...

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. SMX (Security Matters) Public Limited Company (NAS...

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday. Immunic, Inc. (NASDAQ: IMUX)...

THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Tom Garner is joining t...

INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-contr...

U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. Scilex Holding Company (NASDAQ: SCLX)...

THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its participation in the H....